Recent

% | $
Quotes you view appear here for quick access.

3D Systems Corporation Message Board

bemore4224 31 posts  |  Last Activity: May 27, 2016 9:56 AM Member since: Aug 17, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bemore4224 by bemore4224 May 27, 2016 9:56 AM Flag

    Deerfield takes passive stake in Relypsa James Flynn of Deerfield Management disclosed this morning a 5.28% passive stake in Relypsa. The stake represents over 2.36M shares. Shares of Relypsa are up 32% in pre-market trading to $21.84 after the FDA rejected AstraZeneca's (AZN) treatment for hyperkalaemia, a potential competitor to the company's Veltassa.

    Read more at:
    http://thefly.com/landingPageNews.php?id=2381223

  • Reply to

    MTLS now working with Microsoft

    by sulmen2001 May 26, 2016 10:11 AM
    bemore4224 bemore4224 May 26, 2016 3:13 PM Flag

    This would be a steal for HP

    Sentiment: Strong Buy

  • bemore4224 by bemore4224 May 26, 2016 3:03 PM Flag

    Stifel $CEMP (Buy/$17.49; TP:$51.00) : P2 Toyama Data Looks Highly Encouraging – Don’t Underestimate Japan Opportunity

    Sentiment: Strong Buy

  • bemore4224 by bemore4224 May 24, 2016 11:17 AM Flag

    The estimate was for a decision in 6 months. Someone with more knowledge, does it always take this long? They have fast track, antibiotics are in great need. Comments? Thanks- very long

  • bemore4224 by bemore4224 May 24, 2016 11:11 AM Flag

    http://www.businessinsider.com/report-on-economic-effects-of-super-bugs-2016-5

    Sentiment: Strong Buy

  • bemore4224 bemore4224 May 19, 2016 4:58 PM Flag

    Here are the insider trades since the beginning of the yearInsider Trading Insider Buying Insider Selling Large Stock Buying Large Stock Selling Top Traded Stocks
    Stock Screener: Symbol Begin Date: End Date:
    Buy/Sell Transaction Date Acceptance DateTime Issuer Name Issuer Trading Symbol Reporting Owner Name Reporting Owner Relationship Transaction Shares Price per Share Total Value Shares Owned Following Transaction Form
    Buy 2016-02-29 2016-03-16 19:29:35 Relypsa Inc RLYP Harrison Stephen D officer 2,218 $11.2710 $24,999.1000 17,249 Form 4
    Buy 2016-02-29 2016-03-16 19:28:42 Relypsa Inc RLYP Corbett Mary officer 1,274 $11.2710 $14,359.3000 17,454 Form 4
    Buy 2016-03-16 2016-03-16 19:27:16 Relypsa Inc RLYP BALL KRISTINE M officer 7,000 $12.1500 $85,050.0000 28,290 Form 4
    Buy 2016-03-15 2016-03-16 19:26:39 Relypsa Inc RLYP Schuetz Thomas J. director 30,000 $13.3944 $401,832.0000 33,962 Form 4
    you are iggied azzhle.

    Sentiment: Strong Buy

  • bemore4224 by bemore4224 May 13, 2016 5:24 PM Flag

    SOLITAIRE-IV: Results of a Phase 3 IV to Oral Trial in Adults with Community-acquired Bacterial Pneumonia comparing Solithromycin to Moxifloxacin – A62. Clinical Aspects of CAP, HCAP, HAP, and VAP, Poster #P840, Moscone Center, Area G, Hall D (North Building, Lower Level), May 15, 11:00 a.m. PDT. An abstract is available using the link Solithromycin ATS 2016.

  • Reply to

    5 directors bought huge amount shares.

    by drstock2018 May 11, 2016 5:24 PM
    bemore4224 bemore4224 May 11, 2016 6:39 PM Flag

    Insider Buying Screener: Stock Symbol Begin Date: End Date:
    Buy/Sell Transaction Date Acceptance DateTime Issuer Name Issuer Trading Symbol Reporting Owner Name Reporting Owner Relationship Transaction Shares Price per Share Total Value Shares Owned Following Transaction Form
    Buy 2016-05-10 2016-05-11 14:26:38 Endo International plc ENDP KIMMEL ROGER H director 2,000 $15.6600 $31,320.0000 75,362 Form 4
    Buy 2016-05-10 2016-05-11 14:26:38 Endo International plc ENDP KIMMEL ROGER H director 5,000 $15.4800 $77,400.0000 195,000 Form 4
    Buy 2016-05-10 2016-05-11 14:22:03 Endo International plc ENDP HIGGINS ARTHUR J director officer 11,000 $15.4200 $169,620.0000 45,623 Form 4
    Buy 2016-05-10 2016-05-11 14:20:24 Endo International plc ENDP Campanelli Paul officer 13,000 $15.5300 $201,890.0000 201,069 Form 4

  • Reply to

    Vote NO on issuing stock below book value

    by independentstate Apr 5, 2016 10:07 AM
    bemore4224 bemore4224 May 9, 2016 11:45 AM Flag

    guess as to when the new offering comes out? Does management have a pattern with these offerings?

  • bemore4224 bemore4224 May 9, 2016 11:11 AM Flag

    Wall Street has new reason to believe that a dead pharma deal will come back to life.

    Despite being rebuffed last year, Horizon Pharma executives have raised hopes that they will take another run at smaller rival Depomed if that company is forced to put itself up for sale, sources said.

    “They say, ‘Right now we are passive, but if the asset were put into play we would be active participants,’” one large Depomed shareholder told The Post.

    A Horizon spokesman denied the company had spoken to Depomed shareholders but said: “If the Depomed board chose to offer Depomed for sale, and invited Horizon to participate in the bidding, Horizon would evaluate the opportunity anew, as it would any potential acquisition.”

    Depomed, which makes pain treatments among other products, successfully beat back a $3 billion hostile bid from Horizon in November.

    Last week, Depomed settled a lawsuit that had scuttled Horizon’s pursuit of the company. As part of the settlement, Horizon agreed not to initiate another unsolicited takeover of the Depomed until 2020.

    Now, activist investor Starboard, which owns nearly 10 percent of Depomed, has launched a proxy fight to shake up the board and put the company in play again. Starboard has a month to call a special shareholder meeting. Assuming it succeeds, a sale process could follow.

    To defend itself, Depomed has hired proxy adviser Innisfree and plans to meet with shareholders to present its case, sources said. Depomed declined to comment.

    Horizon’s share price has fallen from $38 in July to $13.41, making a stock deal unattractive. But Horizon may be willing to offer cash this time around, sources said.

  • Reply to

    Sanofi

    by bullishonstocks1 May 8, 2016 8:46 PM
    bemore4224 bemore4224 May 9, 2016 10:46 AM Flag

    I wonder if there is a prepayment clause in the loan.

  • Reply to

    AH Sales Agreement With Cowen??

    by golongin2008 May 6, 2016 10:10 PM
    bemore4224 bemore4224 May 8, 2016 10:58 AM Flag

    she has too big of an ego

  • bemore4224 bemore4224 May 4, 2016 3:59 PM Flag

    lowers price target to $31-now trading at 14 and change. Excuse me but that's over %100 gain and she has it at underperform?

    Sentiment: Strong Buy

  • Reply to

    Relentless facts here:

    by angiella22 May 3, 2016 3:23 PM
    bemore4224 bemore4224 May 3, 2016 3:45 PM Flag

    you are iggied azzhle

  • Reply to

    Spam

    by hemmerjohn9 Apr 29, 2016 1:38 PM
    bemore4224 bemore4224 May 1, 2016 8:31 PM Flag

    not sure it will help, report abuse. Yahool won't let you post links but they let this #$%$ go through.

  • Reply to

    I decided to join the class action lawsuit

    by shirazi2001us Apr 23, 2016 10:34 PM
    bemore4224 bemore4224 Apr 24, 2016 10:48 AM Flag

    this p o s is iggied. Lawyers should be used to test the safety of new drugs

  • bemore4224 by bemore4224 Apr 18, 2016 3:22 PM Flag

    1,277 new patients started taking Veltassa with a free-starter supply.
    • 706 outpatient prescriptions were covered by payers and dispensed (retail TRx).
    In the hospital/institution setting:
    • 201 units were sold to hospitals and other institutions (non-retail).
    Overall Quarterly Numbers
    Outpatient setting*
    January 1-31, 2016 February 1-29, 2016 March 1-31, 2016 Q1 Total
    New patients who started taking Veltassa with a free starter-supply
    409
    (average 102
    patients/week)
    812
    (average 203
    patients/week)
    1,277
    (average 290
    patients/week)
    2,498
    Outpatient prescriptions covered and dispensed (retail TRx)
    99
    (average 25
    prescriptions/week)
    350
    (average 87
    prescriptions/week)
    706
    (average 160
    prescriptions/week)
    1,155
    Hospital/institution setting*
    January 1-31, 2016 February 1-29, 2016 March 1-31, 2016 Q1 Total
    Hospital/institution units sold (non-retail)
    56
    (average 14
    units/week)
    117
    (average 29
    units/week)
    201
    (average 46
    units/week)
    374
    * Weekly averages were calculated assuming 4 weeks in January and February and 4.4 weeks in March.

    Sentiment: Strong Buy

  • Reply to

    HZNP Update

    by jansmalo Apr 12, 2016 10:32 AM
    bemore4224 bemore4224 Apr 12, 2016 11:18 AM Flag

    they backed their year end guidance.

  • bemore4224 bemore4224 Apr 7, 2016 2:57 PM Flag

    this short is taking it in the shorts lol

    Sentiment: Strong Buy

  • bemore4224 by bemore4224 Apr 3, 2016 6:43 PM Flag

    NEW YORK (Standard & Poor's) April 1, 2016--Standard & Poor's Ratings Services
    said today that its ratings and outlook on Horizon Pharma plc (B/Stable/--)
    are unaffected by the recent developments--a class action shareholder
    litigation and a proposed share repurchase authorization.

    The class action lawsuit relates to the company's use of patient assistance
    programs as well as the company's relationship with pharmacies. While we will
    monitor developments on that front, we believe it is a longer-term development.

    Separately, the company is currently seeking shareholder approval to
    repurchase up to 16 million shares, which we believe is well within its debt
    capacity for the current ratings. Based on our forecast, the company has
    capacity at the current rating for annual acquisitions and/or share
    repurchases over the next two years, as the company focuses on building its
    core pharmaceutical and orphan drug portfolios.

    Sentiment: Strong Buy

DDD
13.23-0.13(-0.97%)May 27 4:02 PMEDT